Conservation and accessibility of an inner core lipopolysaccharide epitope of Neisseria meningitidis

Infection and Immunity

Volumn 67, Issue 10, 1999, Pages 5417-5426

  Plested, Joyce S ^a,b   Makepeace, Katherine ^a   Jennings, Michael P ^c   Gidney, Margaret Anne J ^d   Lacelle, Suzanne ^d   Brisson, J R ^d   Cox, Andrew D ^d   Martin, Adele ^d   Bird, A Graham ^b   Tang, Christoph M ^a   MacKinnon, Fiona M ^a   Richards, James C ^d   Moxon, E Richard ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; EPITOPE;

ANTIBODY SPECIFICITY; ARTICLE; BACTERIAL MENINGITIS; IMMUNOGENICITY; IMMUNOREACTIVITY; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL;

EID: 0032830633     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.10.5417-5426.1999     Document Type: Article

References (76)

1. Abdillahi, H., and J. T. Poolman. 1988. Typing of group-B Neisseria meningitidis with monoclonal antibodies in the whole-cell ELISA. J. Med. Microbiol. 26:177-180.
2. Al'Aldeen, A. A., and K. A. Cartwright. 1996. Neisseria meningitidis: vaccines and vaccine candidates. J. Infect. 33:153-157.
3. Andersen, S. R., J. Kolberg, E. A. Hoiby, E. Namork, D. A. Caugant, L. O. Pronoun, E. Jantzen, and G. Bjune. 1997. Lipopolysaccharide heterogeneity and escape mechanisms of Neisseria meningitidis: possible consequences for vaccine development. Microb. Pathog. 23:139-155.
4. Apicella, M. A., J. M. Griffiss, and H. Schneider. 1994. Isolation and characterization of lipopolysaccharides, lipooligosaccharides, and lipid A. Methods Enzymol. 235:242-252.
5. Brisson, J. R., S. Uhrinova, R. J. Woods, M. van der Zwan, H. C. Jarrell, L. C. Paoletti, D. L. Kasper, and H. Jennings. 1997. NMR and molecular dynamics of the conformational epitope of the type III group B Streptococcus capsular polysaccharide and derivatives. Biochemistry 36:3278-3292.
6. Buddingh, G. J., and A. Polk. 1937. Meningococcal infection of the chick embryo. Science 86:20-21.
7. Buddingh, G. J., and A. Polk. 1939. Experimental meningococcal infection of the chick embryo. J. Exp. Med. 70:485-498.
8. Cadoz, M. 1998. Potential and limitations of polysaccharide vaccines in infancy. Vaccine 16:1391-1395.
9. Carlin, N. I., M. A. Gidney, A. A. Lindberg, and D. R. Bundle. 1986. Characterization of Shigella flexneri-specific murine monoclonal antibodies by chemically defined glycoconjugates. J. Immunol. 137:2361-2366.
10. Centers for Disease Control. 1990. Availability of meningococcal vaccine in single-dose vials for travellers and high-risk persons. Morbid. Mortal. Weekly Rep. 39:763.
11. Centers for Disease Control. 1997. Communicable disease weekly report, vol. 7, no. 14. Centers for Disease Control, Atlanta, Ga.
12. DeVoe, I. W. 1982. The meningococcus and mechanisms of pathogenicity. Microbiol. Rev. 46:162-190.
13. Di Fabio, J. L., F. Michon, J. R. Brisson, and H. J. Jennings. 1990. Structure of L1 and L6 core oligosaccharide epitopes of Neisseria meningitidis. Can. J. Chem. 68:1029-1034.
14. Finne, J., M. Leinonen, and P. H. Makela. 1983. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet ii:355-357.
15. Frasch, C. E. 1989. Vaccines for prevention of meningococcal disease. Clin. Microbiol. Rev. 2(Suppl.):S134-S138.
16. Gamian, A., M. Beurret, F. Michon, J. R. Brisson, and H. J. Jennings. 1992. Structure of the L2 lipopolysaccharide core oligosaccharides of Neisseria meningitidis. J. Biol. Chem. 267:922-925.
17. Gotschlich, E. C. 1994. Genetic locus for the biosynthesis of the variable portion of Neisseria gonorrhoeae lipooligosaccharide. J. Exp. Med. 180:2181-2190.
18. Griffiss, J. M., J. P. O'Brien, R. Yamensaki, G. D. Williams, P. A. Rice, and H. Schneider. 1987. Physical heterogenicity of neisserial lipopolysaccharides reflects oligosaccharides that differ in apparent molecular weight, chemical composition, and antigenic expression. Infect. Immun. 55:1792-1800.
19. Gu, X. X., and C. M. Tsai. 1993. Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugates. Infect. Immun. 61:1873-1880.
20. Herbert, M. A., P. T. Heath, and R. T. Mayon-White. 1995. Meningococcal vaccines for the United Kingdom. Commun. Dis. Rep. CDR Rev. 5:R130-R135.
21. Holten, E. 1979. Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978. J. Clin. Microbiol. 9:186-188.
22. Hood, D. W., M. E. Deadman, T. Allen, H. Masoud, A. Martin, J. R. Brisson, R. Fleischman, J. C. Venter, J. C. Richards, and E. R. Moxon. 1996. Use of the complete genome sequence information of Haemophilus influenzae Rd to investigate lipopolysaccharide biosynthesis. Mol. Microbiol. 22:951-965.
23. Jennings, H. J. 1989. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development. Contrib. Microbiol. Immunol. 10:151-165.
24. Jennings, H. J., and H. C. Lugowsji. 1981. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J. Immunol. 127:1011-1018.
25. Jennings, H. J., C. Lugowski, and F. E. Ashton. 1984. Conjugation of meningococcal lipopolysaccharide R-type oligosaccharides to tetanus toxoid as route to a potential vaccine against group B Neisseria meningitidis. Infect. Immun. 43:407-412.
26. Jennings, H. J., K. J. Johnson, and L. Kenne. 1983. The structure of an R-type oligosaccharide core obtained from some lipopolysaccharides of Neisseria meningitidis. Carbohydr. Res. 121:233-241.
27. Jennings, H. J., M. Beurret, A. Gamian, and F. Michon. 1987. Structure and immunochemistry of meningococcal lipopolysaccharides. Antonie Leeuwenhoek 53:519-522.
28. Jennings, M. P., D. W. Hood, I. R. Peak, M. Virji, and E. R. Moxon. 1995. Molecular analysis of a locus for the biosynthesis and phase-variable expression of the lacto-N-neotetraose terminal lipopolysaccharide structure in Neisseria meningitidis. Mol. Microbiol. 18:729-740.
29. Jennings, M. P., M. Bisercic, K. L. Dunn, M. Virji, A. Martin, K. E. Wilks, J. C. Richards, and E. R. Moxon. 1995. Cloning and molecular analysis of the lsil (rfaF) gene of Neisseria meningitidis which encodes a heptosyl-2-transferase involved in LPS biosynthesis: evaluation of surface exposed carbohydrates in LPS mediated toxicity for human endothelial cells. Microb. Pathog. 19:391-407.
30. Jennings, M. P., P. van der Ley, K. E. Wilks, D. J. Maskell, J. T. Poolman, and E. R. Moxon. 1993. Cloning and molecular analysis of the galE gene of Neisseria meningitidis and its role in lipopolysaccharide biosynthesis. Mol. Microbiol. 10:361-369.
31. Jonsson, A. B., G. Nyberg, and S. Normark. 1991. Phase variation of gonococcal pili by frameshift mutation in pilC, a novel gene for pilus assembly. EMBO J. 10:477-488.
32. Kogan, G., D. Uhrin, J. R. Brisson, and H. J. Jennings. 1997. Structural basis of the Neisseria meningitidis immunotypes, including the L4 and L7 immunotypes. Carbohydr. Res. 298:191-199.
33. Lepow, M. L., J. Beeler, M. Randolph, J. S. Samuelson, and W. A. Hankins. 1986. Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children. J. Infect. Dis. 154:1033-1036.
34. Lesse, A. J., A. A. Campagnari, W. E. Bittner, and M. A. Apicella. 1990. Increased resolution of lipopolysaccharides and lipopoligosaccharides utilizing tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis. J. Immunol. Methods 126:109-117.
35. Maiden, M. C. J., J. A. Bygraves, E. Feil, G. Morelli, J. E. Russell, R. Urwin, Q. Zhang, J. Zhou, K. Zurth, D. A. Caugant, I. M. Feavers, M. Achtman, and B. G. Spratt. 1998. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc. Natl. Acad. Sci. USA 95:3140-3145.
36. Masoud, H., E. R. Moxon, A. Martin, D. Krajcarski, and J. C. Richards. 1997. Structure of the variable and conserved lipopolysaccharide oligosaccharide epitopes expressed by Haemophilus influenzae serotype b Eagan. Biochemistry 36:2091-2103.
37. Michon, F., M. Beurret, A. Gamian, J. R. Brisson, and H. J. Jennings. 1990. Structure of the L5 lipopolysaccharide core oligosaccharide of Neisseria meningitidis. J. Biol. Chem. 265:7243-7247.
38. Moxon, E. R., D. Hood, and J. C. Richards. 1998. Bacterial lipopolysaccharides: candidate vaccines to prevent Neisseria meningitidis and Haemophilus influenzae infections. Adv. Exp. Med. Biol. 435:237-243.
39. Nassif, X., M. Marceau, C. Pujol, B. Pron, J. L. Beretti, and M. K. Taha. 1997. Type-4 pili and meningococcal adhesiveness. Gene 192:149-153.
40. Neidhardt, F. C. 1996. Derivations and genotypes of some mutant derivatives of Escherichia coli K-12, p. 2460-2488. In F. C. Neidhardt, R. Curtiss III, J. L. Ingraham, E. C. C. Lin, K. Low, Jr., B. Magasanik, W. S. Reznikoff, M. Riley, M. Schaechter, and H. E. Umbarger (ed.), Escherichia coli and Salmonella, 2nd ed. ASM Press, Washington, D.C.
41. Pavliak, V., J. R. Brisson, F. Michon, D. Uhrin, and H. J. Jennings. 1993. Structure of the sialylated L3 lipopolysaccharide of Neisseria meningitidis. J. Biol. Chem. 268:14146-14152.
42. Peltola, H., A. Safary, H. Kayhty, V. Karanko, and F. E. Andre. 1985. Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides. Pediatrics 76:91-96.
43. Peltola, H., H. Makela, H. Kayhty, H. Jousimies, E. Herva, K. Hallstrom, A. Sivonen, O. V. Renkonen, O. Pettay, V. Karanko, P. Ahvonen, and S. Sarna. 1977. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N. Engl. J. Med. 297:686-691.
44. Poolman, J. T. 1990. Polysaccharides and membrane vaccines, p. 57-86. In A. Mizrahi (ed.), Bacterial vaccines. Wiley-Liss, New York, N.Y.
45. Poolman, J. T. 1996. Bacterial outer membrane protein vaccines. The meningococcal example. Adv. Exp. Med. Biol. 397:73-77.
46. Poolman, J. T., C. T. P. Hopman, and H. C. Zanen. 1982. Problems in the definition of meningococcal serotypes. FEMS Microbiol. Lett. 13:339-348.
47. Poolman, J. T., P. van der Ley, and J. P. M. Tommassen. 1995. Surface structures and secreted products of meningococci, p. 21-34. K. Cartwright (ed.), Meningococcal disease. John Wiley & Sons, Inc., New York, N.Y.
48. Preston, A., R. E. Mandrell, B. W. Gibson, and M. A. Apicella. 1996. The lipooligosaccharides of pathogenic gram-negative bacteria. Crit. Rev. Microbiol. 22:139-180.
49. Reingold, A. L., C. V. Broome, G. W. Hightower, G. A. Ajello, C. Bolaw, E. E. Adambauw, C. Jones, H. Phillips, H. Tiendrebeogo, and A. Yada. 1985. Age-specific differences in duration of clinical protection after vaccination with polysaccharide A vaccine. Lancet 11:114-118.
50. Rosenqvist, E., E. A. Hoiby, E. Wedege, K. Bryn, J. Kolberg, A. Klem, E. Ronnild, G. Bjune, and H. Nokleby. 1995. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun. 63:4642-4652.
51. Rosenstein, N., O. Levine, J. P. Taylor, D. Evans, B. D. Plikaytis, J. D. Wenger, and B. A. Perkins. 1998. Efficacy of meningococcal vaccine and barriers to vaccination. JAMA 279:435-439.
52. Sakari, J., N. Pandit, E. R. Moxon, and M. Achtman. 1994. Variable expression of the Opc outer membrane protein in Neisseria meningitidis is caused by size variation of a promoter containing poly-cytidine. Mol. Microbiol. 13: 207-217.
53. Schnaitman, C. A., and F. D. Klena. 1993. Genetics of lipopolysaccharide biosynthesis in enteric bacteria. Microbiol. Rev. 57:655-682.
54. Scholten, R. J., B. Kuipers, H. A. Valkenburg, J. Dankert, W. D. Zollinger, and J. T. Poolman. 1994. Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies. J. Med. Microbiol. 41:236-243.
55. Schroten, H., M. Deadman, and E. R. Moxon. 1995. Development of chick embryo models for analysis of bacterial virulence factors. Pediatr. Grenzgeb. 34:319-324.
56. Seiler, A., R. Reinhardt, J. Sakari, D. A. Caugant, and M. Achtman. 1996. Allelic polymorphisms and site-specific recombination in the ope locus of Neisseria meningitidis. Mol. Microbiol. 19:841-856.
57. Shulman, M., C. D. Wilde, and G. Kohler. 1978. A better cell line for making hybridomas secreting specific antibodies. Nature 276:269-270.
58. Steeghs, L., R. den Hartog, A. den Boer, B. Zomer, P. Roholl, and P. van der Ley. 1998. Meningitis bacterium is viable without endotoxin. Nature 392: 449-450.
59. Stephens, D. S., C. F. McAllister, D. Zhou, F. K. Lee, and M. A. Apicella. 1994. Tn916-generated, lipooligosaccharide mutants of Neisseria meningitidis and Neisseria gonorrhoeae. Infect. Immun. 62:2947-2952.
60. Stern, A., and T. F. Meyer. 1987. Common mechanism controlling phase and antigenic variation in pathogenic neisseriae. Mol. Microbiol. 1:5-12.
61. Stern, A., M. Brown, P. Nickel, and T. F. Meyer. 1986. Opacity genes in Neisseria gonorrhoea: control of phase and antigenic variation. Cell 47:61-71.
62. Stolljkovic, I., V. Hwa, J. Larson, L. Lin, M. So, and X. Nassif. 1997. Cloning and characterization of the Neisseria meningitidis rfaC gene encoding alpha-1,5-heptosyltransferase I. FEMS Microbiol. Lett. 151:41-49.
63. Tonjum, T., and M. Koomey. 1997. The pilus colonization factor of pathogenic neisserial species: organelle biosynthesis and structure/function relationships - a review. Gene 192:155-163.
64. van der Ley, P., M. Kramer, A. Martin, J. C. Richards, and J. T. Poolman. 1997. Analysis of the icsBA locus required for biosynthesis of the inner core region from Neisseria meningitidis lipopolysaccharide. FEMS Microbiol. Lett. 146:247-253.
65. van der Ley, P., M. Kramer, L. Steeghs, B. Kuipers, S. R. Andersen, M. P. Jennings, E. R. Moxon, and J. T. Poolman. 1996. Identification of a locus involved in meningococcal lipopolysaccharide biosynthesis by deletion mutagenesis. Mol. Microbiol. 19:1117-1125.
66. van Putten, J. P., and B. D. Robertson. 1995. Molecular mechanisms and implications for infection of lipopolysaccharide variation in Neisseria. Mol. Microbiol. 16:847-853.
67. Verheul, A. F., A. K. Braat, J. M. Leenhouts, P. Hoogerhout, J. T. Poolman, H. Snippe, and J. Verhoef. 1991. Preparation, characterization, and immunogenicity of meningococcal immunotype L2 and L3.7.9 phosphoethanolamine group-containing oligosaccharide-protein conjugates. Infect. Immun. 59:843-851.
68. Verheul, A. F., H. Snippe, and J. T. Poolman. 1993. Meningococcal lipopolysaccharides: virulence factor and potential vaccine component. Microbiol. Rev. 57:34-49.
69. Verheul, A. F., J. A. Van Gaans, E. J. Wiertz, H. Snippe, J. Verhoef, and J. T. Poolman. 1993. Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specific bactericidal antibodies in mice: influence of adjuvants. Infect. Immun. 61:187-196.
70. Virji, M., H. Kayhty, D. J. P. Ferguson, C. Alexandrescu, J. E. Heckels, and E. R. Moxon. 1991. Interactions of Haemophilus influenzae with cultured human endothelial cells. Microb. Pathog. 10:231-245.
71. Virji, M., H. Kayhty, D. J. P. Ferguson, J. E. Heckels, and E. R. Moxon. 1991. The role of pili in the interactions of pathogenic Neisseria with cultured human endothelial cells. Mol. Microbiol. 5:1831-1841.
72. Wakarchuk, W., A. Martin, M. P. Jennings, E. R. Moxon, and J. C. Richards. 1996. Functional relationships of the genetic locus encoding the glycosyl-transferase enzymes involved in expression of the lacto-N-neotetraose terminal lipopolysaccharide structure in Neisseria meningitidis. J. Biol. Chem. 271:19166-19173.
73. Wakarchuk, W. W., M. Gilbert, A. Martin, Y. Wu, J. R. Brisson, P. Thibault, and J. C. Richards. 1998. Structure of an alpha-2,6-sialylated lipooligosaccharide from Neisseria meningitidis immunotype L1. Eur. J. Biochem. 254: 626-633.
74. Westphal, O., and J. K. Jann. 1965. Bacterial lipopolysaccharides extraction with water-phenol and further applications of the procedure. Methods Carbohydr. Chem. 5:83-91.
75. Wetzler, L. M. 1994. Immunopotentiating ability of neisserial major outer membrane proteins. Use as an adjuvant for poorly immunogenic substances and potential use in vaccines. Ann. N. Y. Acad. Sci. 730:367-370.
76. Zollinger, W. D., E. E. Moran, S. J. Devi, and C. E. Frasch. 1997. Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines. Infect. Immun. 65:1053-1060.